

FEBRUARY 24, 2025

The table below includes a list of the medication policies that were recently reviewed by the Clinical Advisory Committee (CAC), including those that have been approved, revised, or retired. This information is intended for reference only.

For the complete and most current medication policies please visit our online [Medication Policy Library](#).

CAC Meeting Date	Medication Policy	Status
2/24/2025	Anti-Obesity Medication (AOM)*	Updated
2/24/2025	Cayston	Reviewed
2/24/2025	Dupixent	Updated
2/24/2025	Esbriet	Replaced
2/24/2025	Inqovi	Reviewed
2/24/2025	Ofev	Replaced
2/24/2025	Opdivo	Updated
2/24/2025	Promacta	Updated
2/24/2025	Pulmonary Fibrosis Agents*	Updated
2/24/2025	RET Kinase Inhibitors*	Updated
2/24/2025	Votrient	Updated

Legend:

* = Universal Medication Policy

New = Newly developed policy was adopted

Updated = Existing policy was reviewed and revised

Reviewed = Existing policy was reviewed; no changes made

Replaced = Policy was replaced by a new or different policy

Retired = Policy discontinued and removed from active management

For more detailed information about these updates, please refer to the [Medication Policy Summary of Changes – Q1 2025](#) for a comprehensive overview of the latest revisions.

Important Notice:

Medication Policies are developed as needed, regularly reviewed and updated, and are subject to change. Inclusion of a medication within a Medication Policy does **not** guarantee coverage. Coverage determinations must be made in accordance with the benefit plan.

